Type 2 Diabetes, Insulin and a Telehealth GLP-1: The Safety Rules
If you have type 2 diabetes and take insulin or a sulfonylurea (such as glipizide, glyburide or glimepiride), adding a GLP-1 through a weight-loss telehealth platform is not just a weight decision. Every major GLP-1 label as of October 2026 warns that the combination raises the risk of low blood sugar and tells prescribers to consider lowering the insulin or sulfonylurea dose. That means someone has to own your glucose plan, and you should know who before the first shipment arrives.
Key takeaways
- Ozempic, Mounjaro, Wegovy and Zepbound labels all warn that pairing them with insulin or a sulfonylurea can cause hypoglycemia, including severe episodes.
- The labels tell prescribers to consider reducing the insulin or sulfonylurea dose when the GLP-1 starts. A weight-loss platform that does not ask what you take cannot do that.
- Semaglutide labels report more diabetic retinopathy complications in a two-year trial, mainly in people who already had retinopathy. Your eye history belongs in the intake.
- The labels say not to combine a GLP-1 with another GLP-1 or semaglutide product, so a second prescription on top of your Trulicity or Ozempic is a red flag.
- For many people on insulin, the safer route is a telehealth clinician who coordinates with the diabetes clinician already managing those doses.
Why diabetes medications change the telehealth math
GLP-1 drugs lower blood sugar on their own. Insulin and sulfonylureas also lower blood sugar, and they keep working whether or not your glucose is already low. Stack them and the floor can drop out.
The Ozempic prescribing information (revised May 2026) states that using it with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia, and that the risk "may be lowered by a reduction in the dose of sulfonylurea." The Mounjaro prescribing information (revised August 2026) says the same for tirzepatide and adds that prescribers should consider reducing the dose of insulin secretagogues or insulin when starting it.
The weight-loss brands carry the same warning. The Wegovy prescribing information (revised June 2026, covering both the injection and the tablet) advises considering a lower insulin or secretagogue dose. The Zepbound prescribing information (revised August 2026) states plainly that Zepbound lowers blood glucose and gives the same dose-reduction instruction.
What the labels report about low blood sugar
The numbers below come from each label's adverse-reactions section. They are trial rates, not a prediction for you, and they use slightly different definitions, so compare them within a row rather than across drugs.
| Drug and setting | What the label reports |
|---|---|
| Ozempic added to basal insulin (30 weeks) | Severe hypoglycemia: 0% placebo, 0% at 0.5 mg, 1.5% at 1 mg; documented symptomatic (70 mg/dL or lower): 15.2%, 16.7% and 29.8% |
| Ozempic with a sulfonylurea | Severe hypoglycemia 0.8% (0.5 mg) and 1.2% (1 mg); documented symptomatic hypoglycemia 17.3% and 24.4% |
| Mounjaro added to basal insulin (40-week trials) | Glucose below 54 mg/dL: 13% placebo, 16% (5 mg), 19% (10 mg), 14% (15 mg); severe: 0%, 0%, 2%, 1% |
| Mounjaro with a sulfonylurea (up to 104 weeks) | Glucose below 54 mg/dL: 13.8% (5 mg), 9.9% (10 mg), 12.8% (15 mg) |
| Wegovy injection, weight trial in type 2 diabetes | Glucose below 54 mg/dL: 6.2% vs. 2.5% placebo |
| Zepbound, weight trial in type 2 diabetes | Glucose below 54 mg/dL: 4.2% vs. 1.3% placebo; 10.3% among those also on a sulfonylurea vs. 2.1% without |
Source: adverse reactions sections of the Ozempic, Mounjaro, Wegovy and Zepbound prescribing information, as of October 2026.
The Zepbound row is the one to notice if you are shopping weight-loss platforms. Among Zepbound-treated trial participants with type 2 diabetes, the low-glucose rate was roughly five times higher in those also taking a sulfonylurea. That is the exact situation a quick weight-loss intake can miss.
What a careful platform asks before prescribing
A platform that prescribes to people with diabetes should collect more than height, weight and a checkbox. Use this list to judge the intake you are filling out.
- A complete medication list with doses. Insulin type and units, sulfonylurea name and dose, and any other glucose-lowering drug. "Diabetes medication: yes" is not enough to act on.
- A recent A1c and, ideally, glucose readings. The ADA Standards of Care in Diabetes 2026 (Section 9) recommends reevaluating the medication plan at regular intervals, such as every 3 to 6 months, which is hard to do without numbers.
- Whether you already take a GLP-1. The Wegovy and Zepbound labels say coadministration with any other GLP-1 receptor agonist is not recommended. If you are on Trulicity, Victoza, Ozempic or Mounjaro, a weight-loss GLP-1 should replace it under a plan, not stack on top of it.
- Your eye history. Ask whether you have ever been told you have diabetic retinopathy (see below).
- Who manages your diabetes now. A good intake asks for that clinician's name and whether you consent to coordination.
- A plan for lows. The Ozempic and Mounjaro labels say patients on these combinations should be told about hypoglycemia risk and taught its signs and symptoms.
If the intake never asks for any of this, that tells you something about how the platform is built. It may still be legitimate for people without diabetes. It is not set up for you.
Comparing telehealth options?
See how participating providers describe their diabetes screening and care coordination before you sign up.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Who adjusts your insulin or sulfonylurea
This is the question most people skip. When a GLP-1 starts or its dose goes up, something may need to come down. The ADA's 2026 Standards say insulin dosing "should be reassessed upon addition or dose escalation of a GLP-1 RA or dual GIP and GLP-1 RA," and that when starting a new agent clinicians should reassess the need for and dose of sulfonylureas, meglitinides and insulin.
Three workable arrangements exist. Know which one you are in.
| Arrangement | What it looks like | What to check |
|---|---|---|
| Telehealth clinician manages everything | The platform prescribes the GLP-1 and adjusts your insulin or sulfonylurea | Do they review glucose logs or CGM data? How fast do they answer a message about lows? |
| Shared management | The platform prescribes the GLP-1; your diabetes clinician adjusts the other drugs | Has each side agreed to this in writing? Who do you call at 10 p.m. with a reading of 55? |
| Diabetes clinician handles the GLP-1 | You skip the weight platform and ask your current clinician for Ozempic, Mounjaro or another option | Often the simplest path when you are on insulin, and insurance more often covers diabetes-indicated GLP-1s |
Source: dose-adjustment language from the ADA Standards of Care 2026, Section 9 and the prescribing information linked above.
The arrangement to avoid is the unspoken one, where the platform assumes your endocrinologist is handling it and your endocrinologist does not know the GLP-1 exists.
A hypothetical to make it concrete
Hypothetical scenario, not a real patient: Someone takes glimepiride and basal insulin, signs up with a cash-pay weight platform, and lists only "type 2 diabetes, controlled." The platform ships a starting dose. Three weeks later appetite drops, meals shrink, and the same insulin and glimepiride doses now meet much less food. The labels describe exactly this risk. The fix is not complicated, but it only happens if someone with the full medication list is watching.
The retinopathy question
Rapidly improving glucose control can temporarily worsen diabetic eye disease. The Mounjaro and Zepbound labels both state that temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control, and that patients with a history of retinopathy should be monitored.
For semaglutide, the labels give trial numbers. In a two-year cardiovascular trial in type 2 diabetes, diabetic retinopathy complications occurred in 3.0% of Ozempic patients versus 1.8% on placebo, per the Ozempic label. The increase was larger in people who already had retinopathy (8.2% vs. 5.2%) than in those who did not (0.7% vs. 0.4%). The Wegovy label repeats those figures and adds that retinopathy was reported in 4% of Wegovy patients versus 2.7% on placebo in its type 2 diabetes weight trial.
The ADA's 2026 table of glucose-lowering drugs advises close retinopathy monitoring for people at high risk, naming older adults and people who have had type 2 diabetes for 10 years or more, and also says to monitor for NAION (a type of optic nerve damage) during eye exams, per Section 9 of the Standards.
A telehealth clinician cannot look at your retina over video. What they can do is ask about your history, ask when your last dilated eye exam was, and tell you to report vision changes. If no one asks, bring it up yourself.
Other label points that matter more with diabetes
- Gastroparesis. The Ozempic label says it is not recommended in patients with severe gastroparesis. Diabetic gastroparesis is a known complication, so mention any history of it.
- Dehydration and kidneys. The Ozempic label reports postmarketing acute kidney injury, mostly in patients whose nausea, vomiting or diarrhea led to dehydration, and advises monitoring kidney function in patients with those reactions.
- Timing of oral medicines. The Mounjaro label notes that tirzepatide delays gastric emptying and may affect absorption of oral drugs, with extra caution for narrow-therapeutic-index drugs such as warfarin.
- Type 1 diabetes. The Ozempic and Mounjaro indications cover type 2 diabetes. If you have type 1, LADA, or are unsure which type you have, a weight-loss platform is not the place to sort that out.
Weight brand or diabetes brand?
Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight; tirzepatide is Mounjaro for diabetes and Zepbound for weight. Weight-loss platforms usually prescribe the weight brands. With type 2 diabetes, either may be appropriate, and the choice affects coverage. Some plans that exclude weight-loss drugs still cover the diabetes-indicated product, usually with prior authorization, so ask your insurer before paying cash.
That is a reason to ask your existing diabetes clinician first, even if you end up using telehealth for convenience. It is also why compounded versions deserve extra care here: they have no FDA-approved label, so none of the dose-adjustment and retinopathy guidance above was written for them.
A message to send before you start
If you go ahead with a telehealth GLP-1, a short note to the platform and to your diabetes clinician closes most of the gaps. Include:
- Your diagnosis and most recent A1c with its date.
- Every glucose-lowering drug and dose, including insulin units.
- Any history of retinopathy, gastroparesis or kidney disease.
- The GLP-1 being prescribed and the starting dose.
- A direct question: "Who will adjust my insulin or sulfonylurea, and what glucose reading should make me contact you?"
Save both replies. If the answers conflict, resolve that before your first dose.
Where this guide stops
This guide explains what labels and the ADA Standards say. It cannot tell you whether to lower your insulin, by how much, or whether a GLP-1 is right for you. Those are prescriber decisions that depend on your readings, kidney function and history. If you have frequent lows already, use insulin pump therapy, have advanced kidney disease or proliferative retinopathy, the safer default is care with your existing diabetes team, with telehealth as a supplement rather than a replacement.
Ready to compare providers?
Check each provider's licensing, pharmacy and how they handle diabetes medications before you commit.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is it safe to take a GLP-1 with insulin or a sulfonylurea?
It is a common combination, but every major GLP-1 label warns it raises the risk of hypoglycemia, including severe episodes, and tells prescribers to consider lowering the insulin or sulfonylurea dose. Someone needs to own that adjustment.
Who adjusts my insulin if a telehealth platform prescribes my GLP-1?
It depends on the arrangement. Either the telehealth clinician manages all your glucose drugs, or your existing diabetes clinician does with shared communication. Confirm which one in writing before your first dose.
Why does my eye history matter for semaglutide or tirzepatide?
Rapid glucose improvement can temporarily worsen diabetic retinopathy. In a two-year trial, retinopathy complications were more common with semaglutide, mostly in people who already had retinopathy, so labels advise monitoring those patients.
Can I add Wegovy or Zepbound if I already take Ozempic or Trulicity?
The Wegovy and Zepbound labels say coadministration with another GLP-1 receptor agonist is not recommended. A switch should be planned by a prescriber who knows your full medication list.
Sources
- Ozempic (semaglutide) prescribing information, Novo Nordisk, revised 05/2026
- Mounjaro (tirzepatide) prescribing information, Eli Lilly, revised 08/2026
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk, revised 06/2026
- Zepbound (tirzepatide) prescribing information, Eli Lilly, revised 08/2026
- American Diabetes Association: 9. Pharmacologic Approaches to Glycemic Treatment, Standards of Care in Diabetes 2026
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.